Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stem cells more vulnerable to toxic chemotherapy when protective molecule is disabled

19.05.2004


Blocking a molecule that rids cells of potentially toxic molecules might make chemotherapy for leukemia more effective, but it could also leave healthy stem cells more vulnerable to toxic cancer treatment drugs



Inactivating a protective molecule in leukemic cells to make them more vulnerable to chemotherapy might also make healthy blood-forming cells more sensitive to the toxic effects of those same drugs. These findings have been published in the Journal of Biological Chemistry by investigators at St. Jude Children’s Research Hospital.
The St. Jude researchers based their conclusion on results of a study of a molecule whose normal function is to rid hematopoietic stem cells (HSCs) of a potentially toxic molecule called heme. HSCs are the "parent" cells in the bone marrow that give rise to red and white blood cells.

Heme is an oxygen-carrying molecule that is a key part of enzymes used by cells to extract energy from food and by red blood cells to carry oxygen to tissues. The basic building block of heme is porphyrin, which is toxic to cells when it accumulates in high concentrations, according to John Schuetz, Ph.D., associate member in the department of Pharmaceutical Sciences. Schuetz is senior author of the Journal of Biological Chemistry article, which also reports on studies of a molecule called BCRP (breast cancer resistance protein), which protects HSCs from excessive levels of heme.



In conditions of low oxygen, cells tend to compensate by making more heme molecules. But the cells must also protect themselves from excess heme by making BCRP, which is capable of binding to these oxygen-carrying molecules and transporting them out through the cell membrane. The ability of cells to rid themselves of excess heme is especially important in the bone marrow, where HSCs are normally exposed to a low-oxygen environment that stimulates the cells to produce more of this molecule.

In addition to heme, BCRP carries a variety of toxic and carcinogenic chemicals out of cells, including certain drugs used to treat leukemia. Researchers elsewhere are developing molecules to block BCRP in leukemic cells in order to make them more vulnerable to chemotherapy. However, drugs that block BCRP in leukemic cells would also block this molecule in healthy HSCs, leaving them vulnerable to toxic chemotherapy drugs.

"If that happens, the patient’s normal blood-forming cells could be depleted," Schuetz said. "And that would reduce the body’s ability to produce healthy red and white blood cells, which would certainly complicate the patient’s medical condition."

The investigators at St. Jude made their discoveries using bone marrow cells harvested from mice that either carried the gene for BCRP or lacked this gene. In conditions of low oxygen, the HSCs from mice that carried the gene for BCRP multiplied normally, apparently because they were able to rid themselves of excess heme. Similar cells from mice that lacked this gene--and thus could not protect themselves from excess heme--replicated only half as effectively as normal cells. When HSCs from mice carrying the BCRP gene were kept at normal oxygen levels and given the anti-leukemic drug mitoxantrone, 40 percent survived, apparently because they used BCRP to rid themselves of that drug. However, if HSCs from mice lacking the BCRP gene were exposed to mitoxantrone under the same conditions, none of the cells survived.


Other authors of the study were Partha Krishnamurthy, Sheng Zhou, Kelly E. Mercer and Brian P. Sorrentino (St. Jude); Douglas D. Ross, Takeo Nakanishi and Kim Bailey-Dell (University of Maryland School of Medicine); and Balazs Sarkadi (National Medical Center, Budapest Hungary). This work was supported in part by NIH, a Cancer Center support grant, a VA Merit Review Grant, ALSAC and a Howard Hughes International Scholarship.

St. Jude Children’s Research Hospital

St. Jude Children’s Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tennessee, St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization.

Bonnie Cameron | EurekAlert!
Further information:
http://www.stjude.org

More articles from Life Sciences:

nachricht Cancer cachexia: Extracellular ligand helps to prevent muscle loss
25.02.2020 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)

nachricht The genetic secret of night vision
25.02.2020 | Max-Planck-Institut für molekulare Zellbiologie und Genetik

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: High-pressure scientists in Bayreuth discover promising material for information technology

Researchers at the University of Bayreuth have discovered an unusual material: When cooled down to two degrees Celsius, its crystal structure and electronic properties change abruptly and significantly. In this new state, the distances between iron atoms can be tailored with the help of light beams. This opens up intriguing possibilities for application in the field of information technology. The scientists have presented their discovery in the journal "Angewandte Chemie - International Edition". The new findings are the result of close cooperation with partnering facilities in Augsburg, Dresden, Hamburg, and Moscow.

The material is an unusual form of iron oxide with the formula Fe₅O₆. The researchers produced it at a pressure of 15 gigapascals in a high-pressure laboratory...

Im Focus: From China to the South Pole: Joining forces to solve the neutrino mass puzzle

Study by Mainz physicists indicates that the next generation of neutrino experiments may well find the answer to one of the most pressing issues in neutrino physics

Among the most exciting challenges in modern physics is the identification of the neutrino mass ordering. Physicists from the Cluster of Excellence PRISMA+ at...

Im Focus: Therapies without drugs

Fraunhofer researchers are investigating the potential of microimplants to stimulate nerve cells and treat chronic conditions like asthma, diabetes, or Parkinson’s disease. Find out what makes this form of treatment so appealing and which challenges the researchers still have to master.

A study by the Robert Koch Institute has found that one in four women will suffer from weak bladders at some point in their lives. Treatments of this condition...

Im Focus: A step towards controlling spin-dependent petahertz electronics by material defects

The operational speed of semiconductors in various electronic and optoelectronic devices is limited to several gigahertz (a billion oscillations per second). This constrains the upper limit of the operational speed of computing. Now researchers from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg, Germany, and the Indian Institute of Technology in Bombay have explained how these processes can be sped up through the use of light waves and defected solid materials.

Light waves perform several hundred trillion oscillations per second. Hence, it is natural to envision employing light oscillations to drive the electronic...

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Turbomachine expander offers efficient, safe strategy for heating, cooling

25.02.2020 | Power and Electrical Engineering

The seismicity of Mars

25.02.2020 | Earth Sciences

Cancer cachexia: Extracellular ligand helps to prevent muscle loss

25.02.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>